EcoDrugPlus

Prostaglandin E2 Receptor Ep4 Subtype-Like

Ensembl ID : ENSLBEG00000024912
Gene Symbol: LOC109984442
3 Cross references
201 Possible Orthologues:

Prostaglandin E2 Receptor Ep4 Subtype-Like

Ensembl ID : ENSLBEG00000018364
Gene Symbol: LOC109981632
3 Cross references
202 Possible Orthologues:

Prostaglandin F2-Alpha Receptor-Like

Ensembl ID : ENSLBEG00000018446
Gene Symbol: LOC109996097
3 Cross references
195 Possible Orthologues:

Prostaglandin G/h Synthase 1-Like

Ensembl ID : ENSLBEG00000026719
Gene Symbol: LOC109991624
2 Cross references
212 Possible Orthologues:

Prostaglandin I2 Receptor

Ensembl ID : ENSLBEG00000026490
Gene Symbol: PTGIR
3 Cross references
187 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 1

Ensembl ID : ENSLBEG00000027881
Gene Symbol: PTGS1
2 Cross references
182 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 2

Ensembl ID : ENSLBEG00000026283
Gene Symbol: PTGS2
3 Cross references
214 Possible Orthologues:

Proteasomal Ubiquitin Receptor Adrm1-Like

Ensembl ID : ENSLBEG00000009301
Gene Symbol: LOC110000530
3 Cross references
194 Possible Orthologues:

Proteasome 20s Subunit Alpha 1

Ensembl ID : ENSLBEG00000003435
Gene Symbol: PSMA1
3 Cross references
270 Possible Orthologues:

Proteasome 20s Subunit Alpha 2

Ensembl ID : ENSLBEG00000006026
Gene Symbol: PSMA2
3 Cross references
269 Possible Orthologues:

Proteasome 20s Subunit Alpha 3

Ensembl ID : ENSLBEG00000018460
Gene Symbol: PSMA3
3 Cross references
238 Possible Orthologues:

Proteasome 20s Subunit Alpha 4

Ensembl ID : ENSLBEG00000017255
Gene Symbol: PSMA4
4 Cross references
214 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).